Internal medicine

Prostate cancer screening

Cancer screening

Prostate cancer

Prostate-specific antigen

Cancer

Oncology

Intensive care medicine

Randomized controlled trial

Gynecology

Medicine

New England Journal of Medicine

Shoag and colleagues review the long-term results of PSA screening from randomized trials and raise questions about whether the risk–benefit ratio is as strongly in favor of risk over benefit as currently gauged. The decline in PSA screening appears to have been precipitated in part by misinterpretations of data from randomized trials.

Reconsidering the Trade-offs of Prostate Cancer Screening